<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03553875</url>
  </required_header>
  <id_info>
    <org_study_id>2018P001082</org_study_id>
    <nct_id>NCT03553875</nct_id>
  </id_info>
  <brief_title>Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions</brief_title>
  <official_title>Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions: A Randomized-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a 12-week randomized-controlled trial of memantine hydrochloride (Namenda) for
      the treatment of social impairment in youth with Non-Verbal Learning Disorder,
      High-Functioning Autism Spectrum Disorder, and related conditions. Eligible participants will
      be males and females ages 8-18.

      This study consists of up to 6 visits to Massachusetts General Hospital.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression-Improvement Scale (CGI-I)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale (1 to 7-- with higher numbers indicating more severely affected) that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Autism</condition>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Nonverbal Learning Disability</condition>
  <arm_group>
    <arm_group_label>Memantine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Memantine administered in tablet form twice daily titrated to a maximum dose of 20 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in the placebo control group will receive a matched placebo pill with no active ingredients. This will be administered twice daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine Hydrochloride</intervention_name>
    <description>Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to memantine for the course of the 12-week randomized controlled trial (RCT).</description>
    <arm_group_label>Memantine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to placebo for the course of the 12-week randomized controlled trial (RCT).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male &amp; female subjects ages 8-18 years (inclusive).

          -  Diagnostic Statistical Manual (DSM)-5 Autism Spectrum Disorder (ASD) diagnostic
             criteria as established by clinical diagnostic interview

          -  At least moderate severity of social impairment as measured by a total raw score of
             ≥85 on the parent/guardian-completed Social Responsiveness Scale-Second Edition
             (SRS-2)14 and a score of ≥4 on the clinician-administered Clinical Global
             Impression-Severity scale (CGI-S)17.

        Exclusion Criteria:

          -  IQ ≤70 based on the Wechsler Abbreviated Scale of Intelligence-II (WASI-II) Vocabulary
             and Matrix Reasoning subtests

          -  Impaired communicative speech

          -  Subjects currently treated with the following medications (known to impact glutamate
             levels): Lamotrigine, Amantadine, N-acetylcysteine, D-cycloserine

          -  Subjects treated with a psychotropic medication not listed above on a dose that has
             not been stable for at least 4 weeks prior to study baseline.

          -  Co-administration of drugs that compete with memantine for renal elimination using the
             same renal cationic system, including hydrochlorothiazide, triamterene, metformin,
             cimetidine, ranitidine, quinidine, and nicotine

          -  Initiation of a new psychosocial intervention within 30 days prior to randomization.

          -  Subjects who are pregnant and/or nursing.

          -  Subjects with a history of non-febrile seizures without a clear and resolved etiology.

          -  Subjects with a history of or a current liver or kidney disease.

          -  Clinically unstable psychiatric conditions or judged to be at serious suicidal risk.

          -  Subjects who meet on the Kiddie Schedule for Affective Disorders and Schizophrenia
             (K-SADS-E) for alcohol or drug dependence or abuse. If the subject has a recent
             history of substance abuse, there will be a two-week washout period before initiating
             the trial as an added precaution. There are no known safety issues relating to
             memantine and recent history of substance abuse.

          -  Serious, stable or unstable systemic illness including hepatic, renal,
             gastroenterological, respiratory, cardiovascular (including ischemic heart disease),
             endocrinologic, neurologic, immunologic, or hematologic disease.

          -  Subjects with severe hepatic impairment (LFTs &gt; 3 times ULN).

          -  Subjects with genitourinary conditions that raise urine pH (e.g., renal tubular
             acidosis, severe infection of the urinary tract).

          -  Known hypersensitivity to memantine.

          -  Severe allergies or multiple adverse drug reactions.

          -  A history of intolerance or adequate exposure to memantine, as determined by the
             clinician.

          -  Investigator and his/her immediate family defined as the investigator's spouse,
             parent, child, grandparent, or grandchild.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gagan Joshi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nina Dallenbach, BS</last_name>
    <phone>617-724-7079</phone>
    <email>ndallenbach@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haley Driscoll, BA</last_name>
    <phone>617-724-2551</phone>
    <email>hdriscoll2@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Dallenbach, BS</last_name>
      <phone>617-724-7079</phone>
      <email>ndallenbach@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Haley Driscoll, BA</last_name>
      <phone>617-724-2551</phone>
      <email>hdriscoll2@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gagan Joshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Gagan Joshi</investigator_full_name>
    <investigator_title>Director, Autism Spectrum Disorder Program in Pediatric Psychopharmacology</investigator_title>
  </responsible_party>
  <keyword>Autism</keyword>
  <keyword>Massachusetts General Hospital</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Learning Disorders</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Social Communication Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

